The following story appeared on the Channel 7 Network’s current affairs program Today Tonight in May, 2012. Click here to view.
- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
SidebarCategory - Specialised Therapeutics - Page 23
May 11, 2012
May 8, 2012
Royal Melbourne Hospital: First Public Hospital in Australia to Adopt New Technology for Brain Tumour Surgery
Melbourne, Australia May 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital. In 2011, The Royal Melbourne Hospital trialled the drug with great success, and is expected to treat up to an additional 25
April 8, 2012
GLIOLAN® Granted Orphan Drug Status by the Therapeutic Goods Administration
Melbourne, Australia April 2012: A drug which aids neurosurgeons to better visualise and more completely remove malignant brain tumours has been granted orphan drug status by the Therapeutic Goods Administration (TGA). The drug, Gliolan, is currently in-licensed by Melbourne biopharmaceutical company, Specialised Therapeutics Australia (STA) and is currently only available to neurosurgeons via the federal
September 17, 2011
Herald Sun: 17 September, 2011
HERALD SUN (MELBOURNE) By Lucie van den Berg 17 September 2011 Olivia Has a Million Reasons to Smile Olivia Newton-John had one million reasons to be happy yesterday when a Melbourne family made an unprecedented donation to her cancer centre that opens in June.But their generosity reduced the singer to tears. “I’m so touched
August 10, 2011
Specialised Therapeutics Australia Extends Collaboration with Swiss Helsinn Group
Melbourne, Australia and Lugano, Switzerland, 10 August 2011: Melbourne bio-pharmaceutical company Specialised Therapeutics Australia plans to further expand its oncology portfolio, to include a new product for the prevention of chemotherapy-induced nausea and vomiting (CINV). The Australian company has signed a letter of intent with its Swiss partner, Helsinn Group, to in-license Helsinn’s new compound for
June 17, 2011
Specialised Therapeutics to License Brain Tumour Visualisation Drug GLIOLAN® in Australia & NZ
Melbourne, Australia and Hamburg, Germany, 17 June 2011: A new drug which aids neurosurgeons to better visualise and operate on high grade glioma, a type of brain tumour which has a poor prognosis, has been in-licensed by Melbourne bio-pharmaceutical company Specialised Therapeutics Australia Pty Ltd (STA). STA has signed a binding term sheet with German company
May 11, 2011
ABC News: May 2011
The following news clip appeared on the ABC nationally in 2011. Click here to view.
February 21, 2011
World Leading Breast Cancer Drug Now Available in New Zealand
Melbourne, Australia and Auckland, New Zealand – 21 February 2011 – New Zealand women now have access to a leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy. The drug, ABRAXANE, uses novel nanoparticle technology to deliver the chemotherapeutic agent to the tumour site and
November 1, 2010
Specialised Therapeutics and Helsinn Group Announce a PBS Listing for ALOXI® (Palonosetron) in Australia
Melbourne, Australia and Lugano, Switzerland 1st November 2010: A world leading anti-nausea/anti-vomiting drug for cancer patients undergoing chemotherapy will be available in Australia on the Pharmaceutical Benefits Scheme (PBS) from November 1st 2010. Aloxi® (palonosetron hydrochloride) is a new therapy to prevent acute and delayed nausea and vomiting which can occur in cancer patients undergoing chemotherapy1. The
October 20, 2010
Celgene Acquires Abraxis BioScience and Leading Anti-Cancer Drug Abraxane
Melbourne 20 October 2010: Celgene Corporation (NASDAQ: CELG) today announced it has completed its acquisition of Abraxis BioScience, Inc. The transaction adds Abraxane®(nanoparticle albumin-bound paclitaxel) to the company’s existing portfolio of leading cancer products and offers another significant scientific platform that may drive future development.